Followers | 645 |
Posts | 10,613 |
Boards Moderated | 2 |
Alias Born | 03/07/2015 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Quarterly report is out. This is a true merger (see new insider/CEO/CFO/institutional related holdings) for big buisiness. Needs to, and should, play out soon.
https://www.otcmarkets.com/stock/GBHL/disclosure
CRSM: Float 175M; OS unchanged for 3 years; filings regular (gross profits for the last nine quarters)
No Promissory Notes or Convertible Debt
Outstanding Shares 595,304,566 06/30/2023
Outstanding Shares 595,304,566 11/12/2021
https://www.otcmarkets.com/otcapi/company/financial-report/378552/content
Director/CFO holds 310M common shares without ever selling even one!
Outstanding Shares 1,265,434,915 08/13/2023
Restricted 32,345,325 08/13/2023
Unrestricted 1,233,089,590 08/13/2023
They are on top of it...hopefully, revenues after recent merger show up for Q2. 08/14/2023 Notification of Late Filing - Notification Late Filing Q2
financials out! No SS change in a year https://www.otcmarkets.com/stock/PPJE/disclosure
The company is now in the final stages of filing a full patent application for its groundbreaking mycelium thread technology.....At the helm of this groundbreaking project is Dr. Hyder Ali Khoja, the senior lead scientist for the Myco Thread project, whose expertise and vision have been instrumental in unlocking the true potential of mycelium thread. Together with his exceptional team led by Maqsad Suriev, lead project chemist, they have achieved remarkable advancements....
Dr. Khoja expressed, "We have brought together many years of innovative research in a short time to bring forth a more groundbreaking textile than Mushrooms Inc. had expected when filing the provisional patent for mycelium thread.
08/08/2023: Mushrooms, Inc. (OTC: MSRM) is Poised for Textile Innovation and Global Impact as Full Patent Filing for Mycelium Thread Nears Completion
ESTERO, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- via IBN -- Mushrooms Inc. (OTC:MSRM), a trailblazer in sustainable textile innovation, is thrilled to announce a continuation of its mission to revolutionize the textile industry. The company is now in the final stages of filing a full patent application for its groundbreaking mycelium thread technology, representing a significant stride towards a more sustainable and ecologically conscious future while advancing science and technology.
The unique characteristics of the mycelium thread position it as a transformative force across various sectors, spanning medical, military, aerospace, lifestyle, and environmental applications. Drawing from the natural properties of mycelium, coupled with ingenious elements, the textile exhibits inherent antimicrobial qualities and the ability for microbial detection.
"This project showcases that holding to high environmental standards does not mean a sacrifice of technological advancements; in fact, it exemplifies the opposite. By working in partnership with nature, it gives back tenfold," stated CEO Kimberly Carlson of Mushrooms Inc.
While celebrating this pivotal moment, Mushrooms Inc. recognizes the importance of safeguarding its proprietary technology. In this phase, specific details and the intricate science behind the mycelium thread will remain confidential to protect its intellectual property and maintain a competitive edge.
At the helm of this groundbreaking project is Dr. Hyder Ali Khoja, the senior lead scientist for the Myco Thread project, whose expertise and vision have been instrumental in unlocking the true potential of mycelium thread. Together with his exceptional team led by Maqsad Suriev, lead project chemist, they have achieved remarkable advancements that hold the power to revolutionize how textiles are produced and utilized, with profound environmental and functional advantages.
"Dr. Hyder Khoja's role as our senior lead scientist on this project has been indispensable in driving this innovation forward. His diverse accomplishments in science and collaborative dedication have combined to pave the way for the mycelium thread's transformative impact," said Carlson.
Dr. Khoja expressed, "We have brought together many years of innovative research in a short time to bring forth a more groundbreaking textile than Mushrooms Inc. had expected when filing the provisional patent for mycelium thread. We have taken this textile innovation to a new level with microbial detection which we believe, coupled with the natural properties and therapeutic potential of mycelium, will revolutionize the medical sector on a global scale. Being customizable in its attributes allows for endless branches of innovation into vast sectors."
As the patent application undergoes regulatory review, Mushrooms Inc. actively explores strategic partnerships and investment opportunities that align with its mission. The company invites stakeholders, industry partners, and investors who share the vision of a greener, cleaner future to unite in bringing this transformative technology to market.
As Mushrooms Inc. nears the final stages of full patent filing for its innovative mycelium thread technology, the company is strategically planning for its commercialization and global impact. The monetization strategy includes exploring licensing opportunities with industry partners to expand the adoption of this revolutionary textile across various sectors.
Additionally, Mushrooms Inc. is committed to internal development, aiming to bring finished mycelium-based products to market under its brand. The company is also inviting first-use investors who share its vision of sustainable innovation to participate in early-stage funding, ensuring the mycelium thread's rapid integration into the global market. By combining licensing, internal development, and strategic investment, Mushrooms Inc. aims to usher in a new era of eco-friendly textiles and environmentally conscious products for a better, greener world.
Looking forward, Mushrooms Inc. envisions a world where textiles are not just commodities but customizable catalysts for a healthier planet. The company firmly believes that a sustainable future can be achieved through collaborative efforts with nature and a steadfast commitment to innovation.
SKPO's comprehensive list of products (recently updated). They hold a high number of patents incl. for these products:
Dispersants
Skye Chem WD-C (Wax Dispersant - Concentrate)
Wax Dispersant, emulsion breaker, sludge dispersant, viscosity reducer.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/WD-C%20%20TDS%20concentrate%20for%20wax.pdf?ver=1564971876336
Skye Chem AD-C (Asphaltene Dispersant - Concentrate) Ready to Use)
An aqueous proprietary blend of a unique phosphonate and high performance Acrylate Co-polymer. It is used to control the formation of calcium scale and metal oxides in a wide variety of oilfield and industrial formations and applications.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/AD-C%20%20TDS%20concentrate%20for%20asphaltene.pdf?ver=1564971876335
Skye chem WD-RTU
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/SDS%20Skye%20WD-RTU%20-%202016%20January.pdf?ver=1649632935616
Solvents
Skye Chem WD-RTU (Wax Dispersant - Ready to Use)
Solvent surfactant combination for the removal of wax deposits from production strings, formations, pipelines, and vessels.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/WD-RTU%20-%20TDS%20ready%20to%20use%20field%20strength%20for%20w.pdf?ver=1564971510465
Skye Chem AD-RTU (Asphaltene Dispersant - Ready to Use)
Solvent surfactant combination for the removal or asphaltenic deposits from production strings, formations, pipelines, and vessels.
Skye Chem Sludge Buster
A blend of solvents and surfactants designed to disperse hydrocarbon sludges containing a mix of waxes and asphaltenes.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20Sludge%20Buster%20-%20TDS.pdf?ver=1564971510465
Wax Inhibitors
Skye Chem X-110
High molecular weight crystal modifier and dispersant combination. Excellent for high melting point waxes and wax appearance temperature between 30 - 50 C.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20X-110%20TDS_v6.14.pdf?ver=1564971876336
Skye Chem X-112
Polyalkylated phenol - pour point depressant and wax dispersant. Modified to have better cold temperature performance and effective on both microcrystalline wax and intermediate wax appearance temperatures.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20X-112%20TDS_v6.14.pdf?ver=1564971876336
Skye Chem X-115
Very high molecular weight inhibitor for waxes with a melting point range above 60C.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20X-115%20TDS_v6.14.pdf?ver=1564971876336
Skye Chem X-125
A medium molecular weight copolymer ester based pour point depressant. Designed for pour point ranges between 20 and 35C.
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20X-125%20TDS_v6.14.pdf?ver=1564971876336
Skye Chem X-126
An oil soluble wax crystal modifier intended to reduce pour points, modify oil viscosity and change the wax appearance temperature (WAT) or wax crudes with WAT in the range of 10 - 25C. (50 - 80F)
https://img1.wsimg.com/blobby/go/22a24876-35d1-4435-917d-ccc7c080d3b3/downloads/Skye%20Chem%20X-126%20TDS_v6.14.pdf?ver=1564971876336
Summary:
Skye Petroleum, Inc. located in Sugar Land, Texas, offers production chemical treatment services to oil companies that battle flow assurance issues relating to paraffin, asphaltene and sludge. The Company also offers a significant line of Drilling and Completion fluids, as well as a concentrated degreaser agent that has performed extremely well against the competition.
The Production Chemistries, which were developed over several years and sold under the Skye Chem name, are unique as they perform powerfully in many different regions. Skye has reported successful results in suspending paraffin, asphaltene and sludge in many of the major oil producing states in the US; such as, Texas (Permian Basin and Eagle Ford Shale Formations), North Dakota and Pennsylvania, in addition to many other locations. Once the paraffin wax has been returned to liquid form, it will remain in that state all the way to the refinery.
Lab testing has also shown the chemistry to be effective against paraffin wax in other parts of the world. Due to these results, Skye is seeking partners to expand internationally into significant oil producing countries. Skye’s chemistries are effective in oil wells, flowlines, storage tanks, pipelines, vessels, railcars, terminals and refineries.
The chemistry was designed to be effective on a wide range of paraffin waxes and to work quickly. Larry Gatlin, a seasoned veteran in oilfield chemistry, stated that the Skye Chem Wax Dispersant (WD-RTU) chemical is the fastest acting paraffin dispersant he has seen, on the widest number of paraffin samples. Skye Petroleum, Inc. is a publicly traded corporation listed on the OTCMarkets “Current Information” Tier.
SKPO has no convertible notes, minimal OS, the SS has not changed in many years:
Market Cap 712,384
Authorized Shares 290,000,000 07/09/2023
Outstanding Shares 249,959,400 07/09/2023
Restricted 138,532,272 07/09/2023
Unrestricted 111,427,128 07/09/2023
Held at DTC 70,384,931 07/09/2023
call the CEO wanner...last time i did (416-918-6987) right at the time of the "acquisition) he picked up on my first attempt.
6M tradable shares only! 53week high pps $0.014! 2 year high $2.9
Unrestricted: Unchanged
Restricted: Unchanged
OS: Unchanged
Outstanding Shares 38,485,760 08/01/2023
Restricted 32,527,735 08/01/2023
Unrestricted 5,958,025 08/01/2023
seems confirmed...no more large sells into the bid. Anyone interested to gather more might want to consider to get 000s before its too late IMO
Whoever sold these (likely restricted, then converted shares) had a chance to dump into the ~20M bid friday, but didn't....I think they are done with it. Combine that with the tweet about updates any time now......! :)
I hold not too many (280K) but, likewise, will be patient.
Yes. My college age daughter turned $500 into ~$4000 in the last 2 years with occasional logging into her account and, likewise, some OTC ticker flips,,,even she has bought some MSRM 40K shares here to "make her rich" by 2025 :)
And I think thats a nice approach.
After 2 weeks of moderate (in the range of ~6M daily ave) dumps (which I suspect will stop), yet, months without SS change I expect the pps to pick up nicely and with volume easily sail
Yes, but still there would be a discrepancy of ~100M OS between the filing and the reported (needs to come clear) BUT also his shares if sold would be reported as unrestricted, yet, that number (373M) remained the same since 2022
either way the SS is great but the reporting smells right now (maybe he responds by email to this)
Value of unrestricted shares now only 224k! Crazy....
Just some little discrepancy between OTC market (reported through TA)......
Authorized Shares 800,000,000 07/24/2023
Outstanding Shares 579,990,956 07/24/2023
Restricted 206,045,491 07/24/2023
Unrestricted 373,945,465 07/24/2023
And Financial report.....
As of Dec 31, 2022, the OS was 495,741,665 but CEO Martinez got 201,600,000 restricted shares issued March 17, 2023 so the total outstanding was reported in the financials to be 697,341,665 common OS (with 373,945,465 unrestricted and unchanged over a year).
So as you say rightfully they need proper updates plus a clean up of the SS reporting
So the OTC reports only 579,990,956 OS but this is likely wrong (unless some restricted shares were retired after March 31st, which I find unlikely since not reported anywhere).
it smells, indeed. Wasn't even just a one day dump.
SS update = unchanged!
Outstanding Shares 579,990,956 07/24/2023
Restricted 206,045,491 07/24/2023
Unrestricted 373,945,465 07/24/2023
A little remark to the SS: As of Dec 31, 2022, the OS was 495,741,665 but CEO Martinez got 201,600,000 restricted shares issued March 17, 2023 so the total outstanding would be as reported in the financials 697,341,665 common OS (with 373,945,465 unrestricted and unchanged over a year).
Now the OTC reports only 579,990,956 OS but this is likely wrong (unless some restricted shares were retired after March 31st, which I find unlikely since not reported anywhere).
Tx. I typically post only on stocks that I am comfortable about. BUT there were several tickers that I never posted or advised on (yet still got some) over the last two years. And with these I messed up often.
Patiently waiting myself...SS remained unchanged...filings regular...management real...I hold 5M just in case the long awaited surprise kicks in
I finally got my fills. This might be some wait BUT, boy, is this going to spike some day :)
I added yesterday and will EOD again
We will see with the next OTC security update (every few days now) or we could email the TA...nevertheless, so far the SS has been preserved incl. no restricted shares were converted to unrestricted...I have a good feeling (and generally I am very cautious)
Yep...I hold 3M now but am willing to add
No...SS entirely preserved; see below (with no RS history btw.)
Outstanding Shares 579,990,956 07/17/2023
Restricted 206,045,491 07/17/2023
Unrestricted 373,945,465 07/17/2023
Outstanding Shares 579,990,956 04/03/2023
Restricted 206,045,491 04/03/2023
Unrestricted 373,945,465 04/03/2023
Outstanding Shares 98,782,873 7/2023
Restricted 57,391,497 07/19/2023
Unrestricted 41,391,376 07/19/2023
Outstanding Shares 80,142,821 2/2023
Restricted 38,918,110 02/07/2023
Unrestricted 41,224,711 02/07/2023
Outstanding Shares 68,499,406 5/2022
Restricted 39,112,954 05/06/2022
Unrestricted 29,386,452 05/06/2022
Outstanding Shares 25,493,712 7/2021
Outstanding Shares 23,893,712 5/2021
the air is truly out of this balloon...company now even stopped tweeting
alright...got 20M now and will wait for the inevitable spike (market cap just 300k - anything up to a cent pps can happen after CEO shows that he cares about filings and caught up and tweets again)
https://www.otcmarkets.com/stock/MSTO/disclosure
https://twitter.com/masterbeatcorp
https://twitter.com/LlcSbq
MSRM: Mushrooms Inc. CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast.
Estero, FL, July 19, 2023 – Mushrooms Inc. (OTC: MSRM) (the “Company” or “MSRM) is pleased to announce that its CEO, Kimberly Carlson, recently appeared on the esteemed Psychedelic Spotlight Podcast to discuss the exciting potential of the industrial mushroom industry. As the first company trading on the US stock market focused on the industrial side of mushrooms, Mushrooms Inc. is leading the way in revolutionizing this emerging sector.
To watch or listen to the complete interview featuring Kimberly Carlson on Psychedelic Spotlight, please visit the following link: https://psychedelicspotlight.com/using-mycelium-for-a-sustainable-future-feat-kimberly-carlson/
During the podcast episode hosted by David Flores (CEO of Psychedelic Spotlight), Kimberly Carlson shared insights into the vision and mission of Mushrooms Inc. The Company is dedicated to supporting the growth of the mushroom industry through collaboration, innovation, and development. At the heart of Mushrooms Inc. lies a commitment to creating and supporting environmentally beneficial product innovation.
With a specific focus on the industrial application of mycelium, Mushrooms Inc. aims to develop carbon-neutral products for the building, textile, and healthcare industries. By harnessing the power of mycology, Mushrooms Inc. seeks to advance the creation of scientifically proven products that promote the health of the body, mind, and environment which includes remediation of toxic substances using mycelium also known as Myco-remediation.
Along with providing Mr. Flores with an overview of Mushrooms Inc., Ms. Carlson also shared insight into her own personal passion for working within the mushroom sector and why she believes mycelium holds the potential to promote a healthier and more sustainable environment for all of society.
"The potential of the industrial mushroom sector is immense, and Mushrooms Inc. is at the forefront of driving innovation in this field," said Kimberly Carlson, CEO of Mushrooms Inc. "Through our research and development efforts, we are committed to delivering sustainable solutions that benefit not only our customers but also the planet.
I am grateful for the opportunity to have had Mushrooms Inc. featured on the Psychedelic Spotlight Podcast, and more specifically, for the opportunity to provide their audience, as well as many others following the public markets, with an initial introduction into some the exiting things we have planned for MSRM.
In the weeks and months ahead, I look forward to being able to share some of the progress we anticipate making as we strive to truly position MSRM as an industrial mushroom leader.”
Mushrooms Inc. recognizes that true innovation comes from collaboration and learning from pioneers in the field. By fostering working relationships and engaging with experts in mycology, the Company is paving the way for groundbreaking advancements in the industry.
Mushrooms Inc. (OTC: MSRM) Announces Plan for Acquisitions and Vertically Integrated Business Development by Partnering with diversified Mushroom Market LeadersPress Release | 02/23/2023
ESTERO, FL / ACCESSWIRE / February 23, 2023 / Mushrooms, Inc. (OTC PINK:MSRM) (the "Company") has been quietly making progress within this exciting multi-billion-dollar market opportunity currently being opened by new mycelium-based materials science and biotechnology.
Mushrooms Inc. is developing profitable pathways to sustain the research and development branch which is necessary to achieve viable industrial innovation in this new field.
MSRM is targeting grants specific to their goals, working with pioneers, scientists, and universities, on a global scale to develop scientifically proven products that advance health of body, mind, and environment. They have multiple proposals that they are currently reviewing for their costs to bring to market, timelines, scalability, as well as their positive financial, environmental and health impact. These proposals include a patentable process for the development of mycelium-based building supplies, a patentable process for mushroom related cosmetic and anti-aging skin products, a superfood product not currently seen in the marketplace as well as several remediation projects with new product innovation as an end result. These proposals are being assessed while keeping the progress on an off-shore lab and scientists for an evolved patentable mycelium thread.
GROWTH STRATEGY
In order to offset research costs and time on the industrial development side we are establishing pillars of development outside of the industrial mushroom market through acquisitions and joint ventures. The business model is based on the amazing qualities of mycelium and its networking capabilities as well as its ability to benefit from the network its developing.
CEO Kimberly Carlson shared, "I have been fortunate to connect with amazing pioneers and innovators in differing areas of the Mushroom Market in the US and abroad. Three realities have been consistent with the people behind the businesses and their processes. One is that this business model can bring like-minded companies together in order to benefit and fruit from a shared network under the public umbrella. Secondly, there are natural and substantial cross-points between these companies to mutually benefit from each other while growing as a whole. And the third is that there is a desire for many of these businesses to unite their expertise to others and share from a unified gain. By combining the power of shared ideals and resources through joint ventures, we can move as larger more developed companies do, but without limiting quality and compassion for social and environmental governance."
With a focus on profitability and mutually beneficial cross points, MSRM is assessing partnerships with complimentary businesses which would strategically advance the Company's reach into related markets through joint ventures and M&A activity.
Establishing pillars of development outside of the industrial mushroom market allows for a broad scope of proven profitability and cross-sharing of resources.
We seek to enter partnerships in the Cultivation Market, which includes substrate, spawn production, and fruiting. Cultivation gives life to all market pillars to some degree. It feeds directly into the Mushroom Nutraceutical and Medicinal Psylocibin Market with the addition of extraction, quality testing, product development, and processing. The Medicinal Mushroom Market requires legalization and branches into wellness retreats, treatment certifications and clinics.
MSRM is also evaluating several companies involved in the Myco-Remediation Market which uses fungi to clean oil spills, heavy metals, plastics and other pollutants from soil, water, and the atmosphere. All of these markets relate to the industrial and health innovation that the Company is pursuing in differing aspects and creates a connecting point for acceleration, mutual benefit and market share.
It is the belief of MSRM that connecting these pillars of the mushroom market through joint ventures and acquisitions, while focusing their innovation efforts on the industrial side of the market, will garner cross benefits financially and accelerate timelines during the major research and development phases.
We are simultaneously creating a vertically integrated business model for the businesses involved by aligning strengths between the companies under the umbrella of MSRM.
From an investor perspective, we are creating an avenue for investors to support a larger portion of the mushroom market, establishing a broader financial base of support for and from the networked companies while allowing for a more elastic ability to pivot, expand and connect to new industry pathways as they surface.
Market Opportunity
Mushrooms, Inc. operates in the North American segment of the functional mushroom market in the mycelium material and mushroom supplement product types. According to various industrial research firms, the global functional mushroom market is projected to show a compounded annual growth rate of over 9% for the next five years (Industry Arc and Vantage Market Research). The North American edible mushroom market was worth 11.99 billion in 2023 and is growing at a compounded annual growth rate of 9.48%, forecast to reach 20.91 billion by 2028 (Market Data Forecast). The North American functional mushroom market held 33.8% of the global market in 2020 and is growing at a compounded annual growth rate of 7% (Industry Arc).
Overview
Mushrooms, Inc. is a developing-stage emerging consumer products platform focused on the manufacturing and marketing of highly differentiated mushroom-based materials and functional supplements. The core growth pillars of the Mushrooms, Inc. platform are currently based on developing functional mushroom technologies. As a result of growing consumer demand for innovative, sustainable, and carbon-neutral products, Mushrooms, Inc. plans to grow revenues by penetrating the multi-billion-dollar market opportunity currently being opened by new mycelium-based materials science and biotechnology, as well as expanding our platform to include the creation of supplements based on the proven health benefits of mushrooms.
Mushrooms, Inc. seeks to drive the growth of the bourgeoning functional mushroom industry through product innovation and development. Our current core business activity is environmentally beneficial product innovation utilizing self-growing, fibrous, and natural composite materials with controlled physical properties that can be produced in large quantities. Our product technologies focus on mycelium, the main component of fungi. This emerging biotechnology is used in the creation of carbon neutral products for the building, textile, packaging, and health care industries, as well as in the creation of supplements based on the proven health benefits of mushrooms.
Currently, our research focuses primarily on the significant thermal stability of mycelium materials, a result of mycelium's unique degradation qualities that expand the potential fields of application for mushroom-based products. Mushrooms, Inc.'s long-term goal is to build a strong scalable and widely recognized brand that authentically focuses on sustainable mushroom ingredients and novel functionality stemming from innovative biotech and materials science.
For more information, email info@mushroomsinc.com or visit www.mushroomsinc.com
07/19/2023 Mushrooms Inc. CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast Press Release
02/23/2023 Mushrooms Inc. (OTC: MSRM) Announces Plan for Acquisitions and Vertically Integrated Business Development by Partnering with diversified Mushroom Market LeadersPress Release
04/20/2023 Quarterly Report for the period ended March 31, 2023
03/06/2023 Attorney Letter with Respect to Current Information - Shell Status Opinion MSRM
03/06/2023 Attorney Letter with Respect to Current Information - MSRM - Current Information Letter
03/06/2023 Annual Report - MSRM 2022 Annual Report
11/29/2022 Mushrooms, Inc. Announces Name and Ticker Symbol Change on OTC Markets to “MSRM” Press Release
https://www.otcmarkets.com/stock/MSRM/disclosure
08/23/2022 Marijuana Strategic Ventures, Inc. (OTC: MSVI) Now Mushrooms Inc., Announces Filing of Provisional Patent for Novel Mycelium Thread Press Release
Outstanding Shares 38,485,760 07/18/2023
Restricted 32,527,735 07/18/2023
Unrestricted 5,958,025 07/18/2023
Authorized Shares 400,000,000 07/18/2023
update by CEO:
see twitter https://twitter.com/MushroomsInc
MSRM This is totally under the Radar and is REAL. Check the SS , they did file a Patent that is coming up , they do have the product and their Mgt Team actually knows what they are doing.
https://otcmarkets.com/stock/MSRM/security
https://mushroomsinc.com/team-3
https://twitter.com/MushroomsInc
MSRM...Unrestricted shares preserved at 6M...updates:
Mushrooms Inc. CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast.
Estero, FL, July 19, 2023 – Mushrooms Inc. (OTC: MSRM) (the “Company” or “MSRM) is pleased to announce that its CEO, Kimberly Carlson, recently appeared on the esteemed Psychedelic Spotlight Podcast to discuss the exciting potential of the industrial mushroom industry. As the first company trading on the US stock market focused on the industrial side of mushrooms, Mushrooms Inc. is leading the way in revolutionizing this emerging sector.
To watch or listen to the complete interview featuring Kimberly Carlson on Psychedelic Spotlight, please visit the following link: https://psychedelicspotlight.com/using-mycelium-for-a-sustainable-future-feat-kimberly-carlson/
During the podcast episode hosted by David Flores (CEO of Psychedelic Spotlight), Kimberly Carlson shared insights into the vision and mission of Mushrooms Inc. The Company is dedicated to supporting the growth of the mushroom industry through collaboration, innovation, and development. At the heart of Mushrooms Inc. lies a commitment to creating and supporting environmentally beneficial product innovation.
With a specific focus on the industrial application of mycelium, Mushrooms Inc. aims to develop carbon-neutral products for the building, textile, and healthcare industries. By harnessing the power of mycology, Mushrooms Inc. seeks to advance the creation of scientifically proven products that promote the health of the body, mind, and environment which includes remediation of toxic substances using mycelium also known as Myco-remediation.
Along with providing Mr. Flores with an overview of Mushrooms Inc., Ms. Carlson also shared insight into her own personal passion for working within the mushroom sector and why she believes mycelium holds the potential to promote a healthier and more sustainable environment for all of society.
"The potential of the industrial mushroom sector is immense, and Mushrooms Inc. is at the forefront of driving innovation in this field," said Kimberly Carlson, CEO of Mushrooms Inc. "Through our research and development efforts, we are committed to delivering sustainable solutions that benefit not only our customers but also the planet.
I am grateful for the opportunity to have had Mushrooms Inc. featured on the Psychedelic Spotlight Podcast, and more specifically, for the opportunity to provide their audience, as well as many others following the public markets, with an initial introduction into some the exiting things we have planned for MSRM.
In the weeks and months ahead, I look forward to being able to share some of the progress we anticipate making as we strive to truly position MSRM as an industrial mushroom leader.”
Mushrooms Inc. recognizes that true innovation comes from collaboration and learning from pioneers in the field. By fostering working relationships and engaging with experts in mycology, the Company is paving the way for groundbreaking advancements in the industry.
Mushrooms Inc. (OTC: MSRM) Announces Plan for Acquisitions and Vertically Integrated Business Development by Partnering with diversified Mushroom Market LeadersPress Release | 02/23/2023
ESTERO, FL / ACCESSWIRE / February 23, 2023 / Mushrooms, Inc. (OTC PINK:MSRM) (the "Company") has been quietly making progress within this exciting multi-billion-dollar market opportunity currently being opened by new mycelium-based materials science and biotechnology.
Mushrooms Inc. is developing profitable pathways to sustain the research and development branch which is necessary to achieve viable industrial innovation in this new field.
MSRM is targeting grants specific to their goals, working with pioneers, scientists, and universities, on a global scale to develop scientifically proven products that advance health of body, mind, and environment. They have multiple proposals that they are currently reviewing for their costs to bring to market, timelines, scalability, as well as their positive financial, environmental and health impact. These proposals include a patentable process for the development of mycelium-based building supplies, a patentable process for mushroom related cosmetic and anti-aging skin products, a superfood product not currently seen in the marketplace as well as several remediation projects with new product innovation as an end result. These proposals are being assessed while keeping the progress on an off-shore lab and scientists for an evolved patentable mycelium thread.
GROWTH STRATEGY
In order to offset research costs and time on the industrial development side we are establishing pillars of development outside of the industrial mushroom market through acquisitions and joint ventures. The business model is based on the amazing qualities of mycelium and its networking capabilities as well as its ability to benefit from the network its developing.
CEO Kimberly Carlson shared, "I have been fortunate to connect with amazing pioneers and innovators in differing areas of the Mushroom Market in the US and abroad. Three realities have been consistent with the people behind the businesses and their processes. One is that this business model can bring like-minded companies together in order to benefit and fruit from a shared network under the public umbrella. Secondly, there are natural and substantial cross-points between these companies to mutually benefit from each other while growing as a whole. And the third is that there is a desire for many of these businesses to unite their expertise to others and share from a unified gain. By combining the power of shared ideals and resources through joint ventures, we can move as larger more developed companies do, but without limiting quality and compassion for social and environmental governance."
With a focus on profitability and mutually beneficial cross points, MSRM is assessing partnerships with complimentary businesses which would strategically advance the Company's reach into related markets through joint ventures and M&A activity.
Establishing pillars of development outside of the industrial mushroom market allows for a broad scope of proven profitability and cross-sharing of resources.
We seek to enter partnerships in the Cultivation Market, which includes substrate, spawn production, and fruiting. Cultivation gives life to all market pillars to some degree. It feeds directly into the Mushroom Nutraceutical and Medicinal Psylocibin Market with the addition of extraction, quality testing, product development, and processing. The Medicinal Mushroom Market requires legalization and branches into wellness retreats, treatment certifications and clinics.
MSRM is also evaluating several companies involved in the Myco-Remediation Market which uses fungi to clean oil spills, heavy metals, plastics and other pollutants from soil, water, and the atmosphere. All of these markets relate to the industrial and health innovation that the Company is pursuing in differing aspects and creates a connecting point for acceleration, mutual benefit and market share.
It is the belief of MSRM that connecting these pillars of the mushroom market through joint ventures and acquisitions, while focusing their innovation efforts on the industrial side of the market, will garner cross benefits financially and accelerate timelines during the major research and development phases.
We are simultaneously creating a vertically integrated business model for the businesses involved by aligning strengths between the companies under the umbrella of MSRM.
From an investor perspective, we are creating an avenue for investors to support a larger portion of the mushroom market, establishing a broader financial base of support for and from the networked companies while allowing for a more elastic ability to pivot, expand and connect to new industry pathways as they surface.
Market Opportunity
Mushrooms, Inc. operates in the North American segment of the functional mushroom market in the mycelium material and mushroom supplement product types. According to various industrial research firms, the global functional mushroom market is projected to show a compounded annual growth rate of over 9% for the next five years (Industry Arc and Vantage Market Research). The North American edible mushroom market was worth 11.99 billion in 2023 and is growing at a compounded annual growth rate of 9.48%, forecast to reach 20.91 billion by 2028 (Market Data Forecast). The North American functional mushroom market held 33.8% of the global market in 2020 and is growing at a compounded annual growth rate of 7% (Industry Arc).
Overview
Mushrooms, Inc. is a developing-stage emerging consumer products platform focused on the manufacturing and marketing of highly differentiated mushroom-based materials and functional supplements. The core growth pillars of the Mushrooms, Inc. platform are currently based on developing functional mushroom technologies. As a result of growing consumer demand for innovative, sustainable, and carbon-neutral products, Mushrooms, Inc. plans to grow revenues by penetrating the multi-billion-dollar market opportunity currently being opened by new mycelium-based materials science and biotechnology, as well as expanding our platform to include the creation of supplements based on the proven health benefits of mushrooms.
Mushrooms, Inc. seeks to drive the growth of the bourgeoning functional mushroom industry through product innovation and development. Our current core business activity is environmentally beneficial product innovation utilizing self-growing, fibrous, and natural composite materials with controlled physical properties that can be produced in large quantities. Our product technologies focus on mycelium, the main component of fungi. This emerging biotechnology is used in the creation of carbon neutral products for the building, textile, packaging, and health care industries, as well as in the creation of supplements based on the proven health benefits of mushrooms.
Currently, our research focuses primarily on the significant thermal stability of mycelium materials, a result of mycelium's unique degradation qualities that expand the potential fields of application for mushroom-based products. Mushrooms, Inc.'s long-term goal is to build a strong scalable and widely recognized brand that authentically focuses on sustainable mushroom ingredients and novel functionality stemming from innovative biotech and materials science.
For more information, email info@mushroomsinc.com or visit www.mushroomsinc.com
07/19/2023 Mushrooms Inc. CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast Press Release
02/23/2023 Mushrooms Inc. (OTC: MSRM) Announces Plan for Acquisitions and Vertically Integrated Business Development by Partnering with diversified Mushroom Market LeadersPress Release
04/20/2023 Quarterly Report for the period ended March 31, 2023
03/06/2023 Attorney Letter with Respect to Current Information - Shell Status Opinion MSRM
03/06/2023 Attorney Letter with Respect to Current Information - MSRM - Current Information Letter
03/06/2023 Annual Report - MSRM 2022 Annual Report
11/29/2022 Mushrooms, Inc. Announces Name and Ticker Symbol Change on OTC Markets to “MSRM” Press Release
https://www.otcmarkets.com/stock/MSRM/disclosure
08/23/2022 Marijuana Strategic Ventures, Inc. (OTC: MSVI) Now Mushrooms Inc., Announces Filing of Provisional Patent for Novel Mycelium Thread Press Release
Outstanding Shares 38,485,760 07/18/2023
Restricted 32,527,735 07/18/2023
Unrestricted 5,958,025 07/18/2023
Authorized Shares 400,000,000 07/18/2023
update by CEO:
see twitter https://twitter.com/MushroomsInc
MSRM This is totally under the Radar and is REAL. Check the SS , they did file a Patent that is coming up , they do have the product and their Mgt Team actually knows what they are doing.
https://otcmarkets.com/stock/MSRM/security
https://mushroomsinc.com/team-3
https://twitter.com/MushroomsInc
depends at how you look at the entry...2 yrs ago this shot to $pps and exactly 1 year ago to 40cent pps.
Everything's a gamble on the OTC but whether buying at 1.5 cent or 3 cent doesn't matter long term IMO. My ave is ~3.4 cents
see new tweet: @PPJEnterprise 21h
Good morning $PPJE shareholders! We just got our issues sorted! We will move forward from now on. Thank you all for being soo patience! Happy July 18th, 2023! Please Re Tweet!
https://twitter.com/PPJEnterprise
listened myself: CEO is informed, quick thinking, eloquent, determined, business model sound, etc. etc.; esp 12 min in: tiny preserved SS, no convertible notes coming, etc.
CEO is very responsive (emails) but listening to the podcast will reveal way more about her ambitions, goals, approaches. Yes, this industry and sector should offer endless scientific and product opportunities